FindTrial
Sign In

IL13-PE38QQR

DRUG8 trials

Sponsors

INSYS Therapeutics Inc, National Institute of Neurological Disorders and Stroke (NINDS)

Conditions

Anaplastic AstrocytomaAnaplastic OligodendrogliomaBrain NeoplasmGlioblastoma MultiformeGliomaMalignant AstrocytomaMalignant GliomaMixed Oligoastrocytoma

Phase 1

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
CompletedNCT00024557
INSYS Therapeutics IncAnaplastic Astrocytoma, Glioblastoma Multiforme, Malignant Astrocytoma +2
Start: 2001-06-30End: 2007-07-31Target: 40Updated: 2011-06-06
Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
CompletedNCT00024570
INSYS Therapeutics IncAnaplastic Astrocytoma, Glioblastoma Multiforme, Malignant Glioma +1
Start: 2000-11-30End: 2007-07-31Target: 60Updated: 2014-11-14
Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
CompletedNCT00041587
INSYS Therapeutics IncAnaplastic Astrocytoma, Glioblastoma Multiforme, Malignant Glioma +1
Start: 2002-07-31End: 2007-07-31Target: 80Updated: 2011-06-06
Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
CompletedNCT00064779
INSYS Therapeutics IncAnaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma Multiforme +2
Start: 2003-07-31End: 2007-07-31Target: 18Updated: 2011-06-06
IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
CompletedNCT00089427
INSYS Therapeutics IncAnaplastic Astrocytoma, Glioblastoma Multiforme, Oligoastrocytoma
Start: 2004-07-31Target: 24Updated: 2011-07-04
Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma
WithdrawnNCT00378235
INSYS Therapeutics IncRecurrent Malignant Glioma
Updated: 2014-11-13
An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma
TerminatedNCT00880061
National Institute of Neurological Disorders and Stroke (NINDS)Brain Neoplasm, Glioma
Start: 2009-04-07End: 2015-06-05Updated: 2018-07-05

Phase 3

The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
CompletedNCT00076986
INSYS Therapeutics IncGlioblastoma Multiforme
Start: 2004-02-29End: 2007-03-31Target: 300Updated: 2011-06-06

Related Papers

Recurrence patterns and site-level survival in the previous phase III study of IL13-PE38QQR: Implications for drug distribution variability.
Journal of Clinical Oncology2026-05-27
Convection Enhanced Delivery for Diffuse Intrinsic Pontine Glioma: Review of a Single Institution Experience.
2020-07-1421 citations
Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas
Journal of Neurosurgery Pediatrics2014-01-1058 citations